Articles related to TRANSFUSION MEDICINE

Luspatercept demonstrates superior efficacy in achieving transfusion independence for patients with low-risk MDS compared to traditional erythropoiesis-stimulating agents.

In a phase 2 study of nipocalimab for early-onset severe hemolytic disease of the fetus and newborn, 54% of high-risk pregnancies resulted in live births at or after 32 weeks’ gestation without intrauterine transfusions, compared to a historical benchmark of 0%.

In a recent study, 91% of patients with transfusion-dependent β-thalassemia achieved independence from transfusions following treatment with Exagamglogene Autotemcel.

Exa-cel’s success in the CLIMB THAL-111 trial represents a transformative approach to treating β-thalassemia, eliminating dependency on transfusions and underscoring the potential of gene editing in hematological disorders.

In light of recent findings, medical professionals should consider that while liberal transfusion strategies in myocardial infarction patients with anemia do not substantially decrease the risk of further myocardial infarction or death, the restrictive approach’s potential harms should not be overlooked.